Jason Gien
Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 36 | 2024 | 201 | 9.730 |
Why?
| | Extracorporeal Membrane Oxygenation | 17 | 2024 | 290 | 3.450 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 807 | 2.170 |
Why?
| | Hypertension, Pulmonary | 16 | 2022 | 1901 | 1.970 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2023 | 382 | 1.800 |
Why?
| | Persistent Fetal Circulation Syndrome | 7 | 2016 | 137 | 1.610 |
Why?
| | rho-Associated Kinases | 5 | 2016 | 85 | 1.590 |
Why?
| | Infant, Newborn | 47 | 2024 | 6043 | 1.470 |
Why?
| | Neovascularization, Physiologic | 6 | 2013 | 176 | 1.380 |
Why?
| | Pulmonary Artery | 14 | 2018 | 1084 | 1.360 |
Why?
| | Endothelin-1 | 4 | 2016 | 181 | 1.300 |
Why?
| | Endothelial Cells | 10 | 2018 | 779 | 1.280 |
Why?
| | Nitric Oxide | 8 | 2020 | 914 | 1.180 |
Why?
| | Tracheostomy | 5 | 2016 | 132 | 1.010 |
Why?
| | Lung | 16 | 2024 | 4046 | 0.990 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2023 | 38 | 0.880 |
Why?
| | Ostomy | 1 | 2023 | 3 | 0.870 |
Why?
| | Respiration, Artificial | 4 | 2016 | 643 | 0.850 |
Why?
| | Infant | 24 | 2023 | 9408 | 0.810 |
Why?
| | PPAR gamma | 2 | 2013 | 183 | 0.790 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.760 |
Why?
| | Sheep | 14 | 2018 | 854 | 0.760 |
Why?
| | Patient Care Team | 3 | 2016 | 624 | 0.720 |
Why?
| | Ductus Arteriosus, Patent | 3 | 2023 | 51 | 0.700 |
Why?
| | Water-Electrolyte Imbalance | 4 | 2022 | 44 | 0.700 |
Why?
| | Prenatal Diagnosis | 3 | 2024 | 201 | 0.700 |
Why?
| | Retrospective Studies | 35 | 2024 | 15514 | 0.690 |
Why?
| | Length of Stay | 7 | 2019 | 1203 | 0.680 |
Why?
| | Reperfusion Injury | 1 | 2023 | 278 | 0.680 |
Why?
| | Blood Gas Analysis | 2 | 2021 | 74 | 0.670 |
Why?
| | Vasodilator Agents | 4 | 2016 | 333 | 0.640 |
Why?
| | Transportation of Patients | 1 | 2020 | 54 | 0.640 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2023 | 543 | 0.620 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 316 | 0.610 |
Why?
| | Bronchodilator Agents | 1 | 2020 | 248 | 0.590 |
Why?
| | Pregnancy | 20 | 2024 | 6715 | 0.560 |
Why?
| | Shock, Septic | 1 | 2020 | 220 | 0.560 |
Why?
| | Continuity of Patient Care | 2 | 2016 | 279 | 0.530 |
Why?
| | Trachea | 1 | 2018 | 235 | 0.500 |
Why?
| | Ventilator Weaning | 1 | 2016 | 36 | 0.500 |
Why?
| | Humans | 62 | 2024 | 136898 | 0.490 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2015 | 260 | 0.480 |
Why?
| | Hemodynamics | 4 | 2022 | 1114 | 0.480 |
Why?
| | Umbilical Arteries | 1 | 2015 | 54 | 0.470 |
Why?
| | Radial Artery | 1 | 2015 | 69 | 0.470 |
Why?
| | Herniorrhaphy | 3 | 2020 | 60 | 0.460 |
Why?
| | Vasoconstrictor Agents | 2 | 2018 | 137 | 0.450 |
Why?
| | Infant, Premature | 10 | 2023 | 563 | 0.450 |
Why?
| | Sepsis | 2 | 2020 | 610 | 0.450 |
Why?
| | Infant, Extremely Premature | 1 | 2014 | 66 | 0.430 |
Why?
| | Vasopressins | 1 | 2014 | 64 | 0.430 |
Why?
| | Central Nervous System Diseases | 1 | 2014 | 69 | 0.430 |
Why?
| | Female | 43 | 2024 | 72703 | 0.420 |
Why?
| | Weight Gain | 1 | 2017 | 518 | 0.410 |
Why?
| | Hypotension | 1 | 2014 | 123 | 0.410 |
Why?
| | Hernia, Diaphragmatic | 3 | 2021 | 65 | 0.400 |
Why?
| | Patient Discharge | 4 | 2021 | 887 | 0.400 |
Why?
| | Oxygen Consumption | 1 | 2015 | 681 | 0.390 |
Why?
| | Hospital Mortality | 3 | 2021 | 901 | 0.390 |
Why?
| | Gastrostomy | 3 | 2023 | 113 | 0.380 |
Why?
| | Echocardiography | 5 | 2023 | 659 | 0.380 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1575 | 0.370 |
Why?
| | Developmental Disabilities | 1 | 2014 | 265 | 0.370 |
Why?
| | Enzyme Activation | 1 | 2012 | 816 | 0.350 |
Why?
| | Animals, Newborn | 5 | 2023 | 844 | 0.330 |
Why?
| | Communication | 1 | 2016 | 872 | 0.330 |
Why?
| | Pulmonary Alveoli | 4 | 2014 | 405 | 0.310 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3710 | 0.300 |
Why?
| | Endothelium, Vascular | 3 | 2013 | 922 | 0.300 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2022 | 244 | 0.290 |
Why?
| | Kidney | 6 | 2023 | 1460 | 0.290 |
Why?
| | Bacteremia | 3 | 2019 | 209 | 0.290 |
Why?
| | Lung Volume Measurements | 3 | 2023 | 46 | 0.280 |
Why?
| | Sulfonamides | 3 | 2016 | 512 | 0.270 |
Why?
| | Survival Rate | 4 | 2022 | 1972 | 0.270 |
Why?
| | Animals | 18 | 2023 | 36914 | 0.260 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2022 | 389 | 0.260 |
Why?
| | Fetal Growth Retardation | 3 | 2018 | 557 | 0.260 |
Why?
| | Morbidity | 2 | 2023 | 321 | 0.250 |
Why?
| | Fetal Diseases | 1 | 2007 | 171 | 0.250 |
Why?
| | Male | 26 | 2024 | 67308 | 0.240 |
Why?
| | Receptors, Endothelin | 2 | 2016 | 51 | 0.240 |
Why?
| | Risk Factors | 9 | 2021 | 10313 | 0.230 |
Why?
| | Cells, Cultured | 8 | 2014 | 4204 | 0.230 |
Why?
| | Urinary Tract Infections | 4 | 2019 | 166 | 0.230 |
Why?
| | Hirudins | 1 | 2024 | 53 | 0.220 |
Why?
| | Fetus | 6 | 2023 | 803 | 0.220 |
Why?
| | Antithrombins | 1 | 2024 | 59 | 0.220 |
Why?
| | Signal Transduction | 6 | 2018 | 5077 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 88 | 0.210 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 91 | 0.210 |
Why?
| | Endotoxins | 2 | 2015 | 220 | 0.210 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 16 | 0.210 |
Why?
| | Pulmonary Veins | 2 | 2014 | 99 | 0.210 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2013 | 203 | 0.210 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2833 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2022 | 10768 | 0.200 |
Why?
| | Heparin | 1 | 2024 | 259 | 0.200 |
Why?
| | Fundoplication | 2 | 2020 | 54 | 0.200 |
Why?
| | Umbilical Cord | 1 | 2023 | 85 | 0.200 |
Why?
| | Pulmonary Circulation | 4 | 2014 | 430 | 0.200 |
Why?
| | Parturition | 1 | 2023 | 71 | 0.190 |
Why?
| | Tracheobronchomalacia | 1 | 2022 | 14 | 0.190 |
Why?
| | Fetal Blood | 1 | 2024 | 327 | 0.190 |
Why?
| | Tracheomalacia | 1 | 2022 | 17 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 4148 | 0.190 |
Why?
| | Surgical Flaps | 2 | 2023 | 148 | 0.190 |
Why?
| | Gestational Age | 7 | 2021 | 901 | 0.190 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 34 | 0.190 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 31 | 0.180 |
Why?
| | Peptide Fragments | 1 | 2024 | 707 | 0.170 |
Why?
| | Guanylate Cyclase | 2 | 2011 | 37 | 0.170 |
Why?
| | Benzoates | 2 | 2011 | 43 | 0.170 |
Why?
| | Interactive Ventilatory Support | 1 | 2020 | 2 | 0.170 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1790 | 0.170 |
Why?
| | Analgesia | 1 | 2021 | 109 | 0.160 |
Why?
| | Serotonin | 2 | 2013 | 324 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Anticoagulants | 1 | 2024 | 662 | 0.160 |
Why?
| | Infant Mortality | 2 | 2019 | 115 | 0.160 |
Why?
| | Prospective Studies | 5 | 2024 | 7543 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 552 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 153 | 0.160 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2016 | 28 | 0.160 |
Why?
| | Heart Atria | 1 | 2020 | 136 | 0.150 |
Why?
| | Heart Failure | 2 | 2022 | 2210 | 0.150 |
Why?
| | Diuretics | 2 | 2018 | 74 | 0.150 |
Why?
| | Rats | 4 | 2023 | 5675 | 0.150 |
Why?
| | Asphyxia Neonatorum | 1 | 2018 | 18 | 0.150 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 220 | 0.150 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2018 | 26 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 173 | 0.150 |
Why?
| | Cell Proliferation | 3 | 2015 | 2471 | 0.140 |
Why?
| | Disease Models, Animal | 5 | 2015 | 4281 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 86 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 703 | 0.140 |
Why?
| | Child | 8 | 2022 | 21896 | 0.140 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 267 | 0.140 |
Why?
| | Survival Analysis | 2 | 2020 | 1320 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 5 | 2018 | 248 | 0.140 |
Why?
| | Administration, Inhalation | 2 | 2016 | 682 | 0.140 |
Why?
| | Blood Vessels | 2 | 2016 | 187 | 0.140 |
Why?
| | Brain Diseases | 1 | 2018 | 141 | 0.140 |
Why?
| | Injections, Intraperitoneal | 1 | 2016 | 115 | 0.130 |
Why?
| | Infant Care | 1 | 2016 | 45 | 0.130 |
Why?
| | Expectorants | 1 | 2016 | 24 | 0.130 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 65 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 3 | 2016 | 2500 | 0.130 |
Why?
| | Ventilators, Mechanical | 1 | 2016 | 58 | 0.130 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2016 | 145 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.120 |
Why?
| | Bacterial Infections | 1 | 2018 | 248 | 0.120 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 386 | 0.120 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 17 | 0.120 |
Why?
| | Cross Infection | 1 | 2018 | 238 | 0.120 |
Why?
| | Steroids | 1 | 2016 | 166 | 0.120 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 259 | 0.120 |
Why?
| | Receptors, Calcitriol | 1 | 2015 | 55 | 0.120 |
Why?
| | Preoperative Care | 1 | 2017 | 356 | 0.120 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 45 | 0.120 |
Why?
| | Bleomycin | 1 | 2016 | 247 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2030 | 0.120 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 260 | 0.120 |
Why?
| | Databases, Factual | 5 | 2018 | 1345 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2024 | 3528 | 0.120 |
Why?
| | Piperidines | 1 | 2016 | 207 | 0.120 |
Why?
| | Catalase | 1 | 2015 | 131 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 273 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 320 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 316 | 0.110 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 53 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2015 | 80 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 88 | 0.110 |
Why?
| | Arteriovenous Fistula | 1 | 2014 | 36 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 1 | 2015 | 133 | 0.110 |
Why?
| | Cyclic GMP | 2 | 2011 | 94 | 0.110 |
Why?
| | Coculture Techniques | 1 | 2015 | 240 | 0.110 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2013 | 62 | 0.110 |
Why?
| | Capillaries | 1 | 2014 | 108 | 0.110 |
Why?
| | Logistic Models | 4 | 2020 | 2060 | 0.100 |
Why?
| | Pregnancy Trimester, Third | 2 | 2024 | 113 | 0.100 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 20 | 0.100 |
Why?
| | Ligation | 1 | 2012 | 87 | 0.100 |
Why?
| | Ductus Arteriosus | 1 | 2012 | 73 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 346 | 0.100 |
Why?
| | Vitamins | 1 | 2014 | 176 | 0.100 |
Why?
| | Diaphragm | 2 | 2023 | 42 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 620 | 0.100 |
Why?
| | Amides | 1 | 2012 | 93 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1739 | 0.100 |
Why?
| | Hospitalization | 2 | 2021 | 2183 | 0.090 |
Why?
| | Pyridines | 2 | 2012 | 504 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 619 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 344 | 0.090 |
Why?
| | DNA Primers | 1 | 2012 | 514 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 463 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1108 | 0.090 |
Why?
| | Isoenzymes | 1 | 2011 | 305 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 853 | 0.080 |
Why?
| | Vitamin D | 1 | 2014 | 392 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 165 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 849 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2222 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1227 | 0.080 |
Why?
| | Ultrasonography, Prenatal | 2 | 2022 | 284 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1324 | 0.080 |
Why?
| | Amniotic Fluid | 2 | 2024 | 95 | 0.080 |
Why?
| | Prognosis | 3 | 2023 | 4011 | 0.080 |
Why?
| | Vasodilation | 2 | 2011 | 494 | 0.080 |
Why?
| | Hypoxia | 1 | 2016 | 1106 | 0.080 |
Why?
| | Myosin-Light-Chain Phosphatase | 1 | 2008 | 3 | 0.080 |
Why?
| | Dipeptides | 1 | 2008 | 50 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 346 | 0.070 |
Why?
| | Nitroarginine | 1 | 2007 | 57 | 0.070 |
Why?
| | Phosphorylation | 2 | 2011 | 1762 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1154 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 845 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2783 | 0.070 |
Why?
| | Pilot Projects | 2 | 2024 | 1684 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1774 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 2627 | 0.070 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 241 | 0.070 |
Why?
| | Oxadiazoles | 3 | 2011 | 35 | 0.070 |
Why?
| | Vascular Resistance | 3 | 2013 | 372 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2006 | 106 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 795 | 0.060 |
Why?
| | Hyperoxia | 1 | 2006 | 90 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 533 | 0.060 |
Why?
| | Child, Preschool | 2 | 2020 | 11013 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1357 | 0.060 |
Why?
| | Cell Membrane | 1 | 2008 | 751 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 1063 | 0.060 |
Why?
| | Phenotype | 2 | 2016 | 3201 | 0.060 |
Why?
| | Fetal Development | 1 | 2007 | 296 | 0.060 |
Why?
| | Adult | 4 | 2024 | 37595 | 0.050 |
Why?
| | Indomethacin | 1 | 2023 | 81 | 0.050 |
Why?
| | Liver | 2 | 2022 | 1937 | 0.050 |
Why?
| | Ketanserin | 2 | 2013 | 12 | 0.050 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.050 |
Why?
| | Sertraline | 2 | 2013 | 30 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1773 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2022 | 34 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 500 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 153 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 66 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 8 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3432 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 13157 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 193 | 0.040 |
Why?
| | Intubation | 1 | 2018 | 3 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2022 | 528 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 210 | 0.040 |
Why?
| | Oligohydramnios | 1 | 2018 | 12 | 0.040 |
Why?
| | Polyhydramnios | 1 | 2018 | 17 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 160 | 0.040 |
Why?
| | Apgar Score | 1 | 2018 | 17 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 94 | 0.040 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 40 | 0.040 |
Why?
| | Heart | 1 | 2022 | 660 | 0.040 |
Why?
| | Surgical Mesh | 1 | 2018 | 49 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 120 | 0.040 |
Why?
| | Time Factors | 2 | 2020 | 6802 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 87 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 139 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 229 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 170 | 0.030 |
Why?
| | Pneumonia | 2 | 2018 | 631 | 0.030 |
Why?
| | Gene Expression | 2 | 2013 | 1505 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 566 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 520 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 2018 | 111 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 126 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 156 | 0.030 |
Why?
| | Adolescent | 1 | 2016 | 21402 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 540 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 268 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1058 | 0.030 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 114 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2066 | 0.030 |
Why?
| | Postpartum Period | 1 | 2019 | 341 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2015 | 15 | 0.030 |
Why?
| | Calcifediol | 1 | 2015 | 33 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2016 | 78 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 514 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 451 | 0.030 |
Why?
| | United States | 3 | 2018 | 14595 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 815 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2020 | 792 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 882 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 195 | 0.030 |
Why?
| | Sheep, Domestic | 1 | 2013 | 34 | 0.030 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 160 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 993 | 0.030 |
Why?
| | Tryptophan Hydroxylase | 1 | 2013 | 53 | 0.030 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 198 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1524 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3290 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 413 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 9 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 26 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 34 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 69 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2011 | 105 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 54 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 830 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5711 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 172 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 624 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2006 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 227 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1460 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 320 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 437 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 69 | 0.020 |
Why?
| | Piperazines | 1 | 2011 | 349 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 943 | 0.020 |
Why?
| | Acetylcholine | 1 | 2009 | 186 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 411 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2709 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 971 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 446 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 479 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 973 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2389 | 0.010 |
Why?
|
|
Gien's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|